FFAR2 and colorectal carcinoma: Migration and invasion of CRC cells were decreased after FFAR2 and FFAR4 agonist treatments (Fig. 2c, S3a-b) suggesting that FFARs stimulation inhibits metastatic properties of CRC cells.